A Clinical Trial of Timolol and Epinephrine in the Treatment of Primary Open-angle Glaucoma

Alexander, Deborah W.; Berson, Frank G.; Epstein, David L.

doi:10.1016/s0161-6420(88)33205-7

Cited by 21 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparing the present study with a 1-year, openlabel trial with dorzolamide in 333 patients, the magnitude of the IOP reduction was less, the dropout rate because of inadequate IOP control was greater, and the proportion of patients requiring adjunctive therapy with timolol was greater in the dorzolamide trial. 9 Overall withdrawal rates, especially those resulting from the development of adverse side effects, were greater for dorzolamide, 9 apraclonidine, 10 -12 brimonidine, 13 epinephrine, 14,15 miotics, 16 and oral carbonic anhydrase inhibitors. 16 Systemic adverse events resulting in discontinuation of timolol treatment occur in 15% to 25% of patients.…”

Section: Discussionmentioning

confidence: 99%

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol

Camras

Wax

Ritch

et al. 1998

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol

Camras

Wax

Ritch

et al. 1998

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Noteworthy is the fact that dipivefrin or epinephrine administered to humans should be considered as producing a moderate hypotensive effect. The long-term ocular hypotensive effect of epinephrine is similar or slightly worse than that achieved with timolol (Alexander et al 1988). Dipivefrin is less potent than most β-blockers with exception of, perhaps, betaxolol 0.25% (Albracht et al 1993).…”

Section: Mechanism Of Actionmentioning

confidence: 93%

Autonomic drugs in the treatment of canine and feline glaucoma – Part I: Medications that lower intraocular pressure by increasing the outflow of aqueous humour

Maślanka¹

2014

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

One characteristic of the most common types of glaucoma is increased intraocular pressure (IOP), which has a damaging effect on optic nerve axons, leading to progressive loss of retinal ganglion cells. Therefore, ocular hypotensive drugs are the mainstay of pharmacological therapy for glaucoma. This review article, which is the first part of a two-part series, is dedicated to autonomic drugs which lower IOP by increasing the outflow of aqueous humour. These agents are subdivided into two groups: (a) drugs that lower IOP by increasing the trabecular outflow and the uveoscleral outflow (i.e. nonselective adrenergic agonists), and (b) medications that lower IOP by opening of the drainage angle and by increasing the conventional outflow via the trabecular outflow (i.e. parasympathomimetics). This paper summarizes the current state of knowledge on the mechanism of action of these drugs and their effect on IOP in dogs and cats. Moreover, it discusses possible undesirable side effects of these medications and presents the current ideas about their role and position in the medical management of glaucoma in small animals.

show abstract

“…Eleven trials restricted entry to participants with OHT (Epstein 1989;Heijl 2000;Kamal 2003;Kass 1989;Kass 2002;Kitazawa 1990;EGPS 2005;Ravalico 1994;Schulzer 1991;Schwartz 1995;Wishart 1992). Six trials accepted both POAG and OHT participants (Alexander 1988;Collignon-Brach 1994;Geyer 1988;Leblanc 1998;Novack 1989;Schuman 1997).…”

Section: Sample Characteristicsmentioning

confidence: 99%

Medical interventions for primary open angle glaucoma and ocular hypertension

Vass

Hirn

Sycha

et al. 2007

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Analysis 2.1. Comparison 2 Comparison of timolol and carteolol, Outcome 1 Incidence of visual field defect progression.......... Analysis 3.1. Comparison 3 Comparison of timolol and levobunolol, Outcome 1 Incidence of visual field defect progression....... Analysis 3.2. Comparison 3 Comparison of timolol and levobunolol, Outcome 2 Drop-out due to drug-related adverse events..... Analysis 4.1. Comparison 4 Comparisons of timolol and betaxolol, Outcome 1 Change of visual field mean sensitivity............... Analysis 4.2. Comparison 4 Comparisons of timolol and betaxolol, Outcome 2 Drop-out due to drug-related adverse events...... Analysis 5.1. Comparison 5 Comparison of timolol and brimonidine, Outcome 1 Incidence of visual field defect progression...... Analysis 5.2. Comparison 5 Comparison of timolol and brimonidine, Outcome 2 Drop-out due to drug-related adverse events..... Analysis 6.1. Comparison 6 All treatments versus placebo or untreated, Outcome 1 Incidence of visual field defect progression.... Analysis 6.2. Comparison 6 All treatments versus placebo or untreated, Outcome 2 Sensitivity analysis concerning the incidence of visual field progression.

show abstract

A Clinical Trial of Timolol and Epinephrine in the Treatment of Primary Open-angle Glaucoma

Cited by 21 publications

References 14 publications

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol

Autonomic drugs in the treatment of canine and feline glaucoma – Part I: Medications that lower intraocular pressure by increasing the outflow of aqueous humour

Medical interventions for primary open angle glaucoma and ocular hypertension

Contact Info

Product

Resources

About